Portal de investigación
ESTUDIO EN FASE 3, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO, DE DOS AÑOS DE TRATAMIENTO, PARA EVALUAR LA EFICACIA Y LA SEGURIDAD A LARGO PLAZO DE CP-945.598 EN EL TRATAMIENTO DE SUJETOS OBESOS.
Datos básicos
- Protocolo:
- A5351019
- EUDRACT:
- 2006-005084-26
- NCT:
- Centro:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
Data mining analyses for precision medicine in acromegaly: a proof of concept.
Gil, Joan; (...); Puig-Domingo, Manel
Article. 10.1038/s41598-022-12955-2. 2022
Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas. A series of 604 cases.
Araujo-Castro, Marta; (...); Puig-Domingo, Manel
Article. 10.1210/clinem/dgae126. 2024
Effectiveness of Combined First-Line Medical Treatment in Acromegaly with Prolactin Co-secretion.
Biagetti, Betina; (...); Puig-Domingo, Manel
Article. 10.1093/ejendo/lvae053. 2024
Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain.
Lamas C; (...); Soto A
Article. 10.3389/fendo.2023.1204206. 2023
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.
Araujo-Castro M; (...); Puig-Domingo M
Correction. 10.1530/ERC-24-0043e. 2024
Glucose metabolism outcomes after pituitary surgery in patients with acromegaly.
Pascual-Corrales, Eider; (...); Araujo-Castro, Marta
Article. 10.1007/s11102-024-01415-x. 2024
Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response.
Gil J; (...); Puig-Domingo M
Article. 10.3390/biomedicines10020460. 2022
Integrative Clinical, Hormonal and Molecular Data associate with Invasiveness in Acromegaly: REMAH Study.
Sampedro-Nunez, Miguel; (...); Luque, Raul M
Article. 10.1093/ejendo/lvae045. 2024
Integrative clinical, radiological and molecular analysis for predicting remission and recurrence of Cushing's disease.
Moreno-Moreno, Paloma; (...); Luque, Raul M.
Article. 10.1210/clinem/dgac172. 2022
Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly.
Ruiz, Sabina; (...); Puig-Domingo, Manel
Article. 10.1111/cen.14946. 2023
Mortality in acromegaly diagnosed in the elderly in Spain is higher in women compared to the general Spanish population.
Biagetti, Betina; (...); Puig-Domingo, Manel
Article. 10.1210/clinem/dgad141. 2023
Outcomes of transsphenoidal surgery for pituitary adenomas in Spain: a retrospective multicenter study.
Paja, Miguel; (...); Biagetti, Betina
Article. 10.3389/fendo.2025.1529418. 2025
Pegvisomant or pasirotide in PRL and GH co-secreting vs GH-secreting Pit-NETs.
Araujo-Castro, Marta; (...); Puig-Domingo, Manel
Article. 10.1530/ERC-24-0043. 2024
Personalized medicine in acromegaly: The ACROFAST study.
Marques-Pamies, Montserrat; (...); Puig-Domingo, Manel
Article. 10.1210/clinem/dgae444. 2024
Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly.
Marques-Pamies M; (...); Puig-Domingo M
Article. 10.3389/fendo.2023.1269787. 2023
Trends and Outcomes in Pituitary Apoplexy Management: A Spanish Observational Multicenter Study.
Biagetti, Betina; (...); Puig-Domingo, Manel
Article. 10.1227/neu.0000000000003281. 2024